Collection Periodical Articles [327/330] Books/Book Section [1/1] Conference Papers/Meeting Abstract [115/179] Siblings Winston C.Y. Yu [19/19] Ko-Jiunn Liu [85/98] Tsang-Wu Liu [119/125] Jieh-Yuan Liou(2003-2010) [3/3] Her-Shyong Shiah(1996-2012) [26/31] Shine-Gwo Shiah [51/54] Nai-Jung Chiang [82/94] Hui-Ju Mandy Ch'ang [39/44] Jang-Yang Chang [234/254] Kwang-Yu Chang [69/79] I-Shou Chang [103/106] Wun-Shaing Wayne Chang [52/53] Jeffrey Shu-Ming [89/91] Jacqueline Whang-Peng(1996-2007) [120/126] Neng-Yao Shih [37/43] Chia-Huei Lee [29/29] Alan Yueh-Luen Lee [48/49] Su-Fang Lin [32/32] Yi-Hsin Yang [41/42] Shih-Sheng Jiang [88/90] Che-Hung Shen [14/16] Wen-Chun Hung [88/88] Shuang-En Chuang [82/91] Kelvin Kun-Chih Tsai [32/34] Hui-Jen Tsai [66/71] Yung-Yeh Su [40/40] Jen-Liang Su [24/25] Ching-Chuan Kuo [71/76] Shang-Hung Chen [45/48] Jen-Yang Chen [72/72] Mei-Shya Chen(2002-2009) [1/1] Shih-Cheng Chen [2/2] Ya-Wen Chen [38/39] Tze-Sing Huang [55/55] Dau-Yang Huang [26/26] Chou-Chik George Ting(2000-2004) [5/5] Others [464/471] Ming Jacqueline Liu(1996-2007) [60/62] Mei-Ying Liu(2004-2006) [2/2] Cheng-Wen Wu(1996-2008) [53/55] Szu-Wen Tseng(1997-2007) [4/4] Kuan-Te Li(1997-2004) [4/6] Ching-Tai Lin(1999-2007) [5/5] Wen-Kuang Yang(1996-1999) [21/21] Chuan-Cheng Wang(1996-2003) [4/4] Shin-Hun P. Juang(1997-2004) [11/11] Tzung-Huang Jan(2000-2008) [2/2] Gi-Ming Lai(2004-2008) [41/47] Li-Jung Juan(2000-2006) [6/7] Jim-Ray Chen(2003-2007) [6/6] Yen-Ying Ma(1997-1999) [1/1] Chi-Ying F. Huang(2005-2007) [9/10] Community Statistics Item counts issued in 3 years:74(14.51%) Items With Fulltext:443(86.86%) Download counts of the item Download times greater than 0:443(100.00%) Download times greater than 100:425(95.94%) Total Bitstream Download Counts:177337(3.31%) Last Update: 2024-11-28 17:46 Top Upload Loading... Top Download Loading... Recent Submissions Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 176-200 of 510. (21 Page(s) Totally) << < 3 4 5 6 7 8 9 10 11 12 > >> View [10|25|50] records per page

Date	Title	Relation
2018-10	Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
2018-10	NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
2018-10	The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
2018-10	Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1	Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.
2018-10	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P.
2018-10	Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD.
2018-09	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286.
2018-08-24	BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor	Cancer Science. 2018 Nov;109(11):3591-3601.
2018-07	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients	Journal of the Chinese Medical Association. 2018 Jul;81(7):593-598.
2018-06	Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma	Annals of Oncology. 2018 Jun;29(6):1402-1408.
2018-06	The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
2018-06	Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
2018-06	Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150.
2018-06	Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004.
2018-06	Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151.
2018-05	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127.
2018-05	A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers	Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556.
2018-05	A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204.
2018-04	The role of consolidation chemoradiotherapy in Locally Advanced Pancreatic Cancer receiving chemotherapy: An updated systematic review and meta-analysis	Cancer Research and Treatment. 2018 Apr;50(2):562-574.
2018-04	Dialysis increases the risk of bladder recurrence in patients with Upper Tract Urothelial Cancer: A population-based study	Annals of Surgical Oncology. 2018 Apr;25(4):1086-1093.
2018-03	Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use	Kaohsiung Journal of Medical Sciences. 2018 Mar;34(3):181-183.
2018-03	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy	Journal of Cancer Research and Practice. 2018 Mar;5(1):27-31.
2018-02-01	Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development	OncoImmunology. 2018 Feb 1;7(5):Article number e1424612.
2018-02	Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.
2018-02	Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459.

Showing items 176-200 of 510. (21 Page(s) Totally) << < 3 4 5 6 7 8 9 10 11 12 > >> View [10|25|50] records per page